Table 4 PLR studies in genitourinary and gynecological malignancies
Year | Article | Total N | Study end-point(s) | Disease(s) | Treatment(s) | Important results |
|---|---|---|---|---|---|---|
2015 | Langsenlehner et al. [19] | 374 | MFS, CSS, OS, Biochemical DFS | Prostate ca. | RT | High pretreatment PLR (PLR ≥ 190) was associated with poor MFS, CSS and OS in multivariate analysis |
2022 | Huszno et al. [58] | 152 | OS | Prostate ca. | RT (81.6%)/S (13.8%) | Pretreatment PLR was not associated with OS |
2018 | Ma et al. [34] | 3668 (12 studies) | OS, DFS, PFS | Cervix ca. | CRT, mixed, surgery | Elevated pretreatment PLR was significantly correlated with poor OS, DFS/PFS; elevated pretreatment PLR was highly correlated with lymphovascular invasion (+), lymph node metastasis (+), tumor size (> 4 cm), and grade (G3) |
2022 | Chauhan et al. [59] | 90 | Clinical response | Cervix ca. | CRT | High pretreatment PLR was significantly associated with poor response (AUC = 0.626) |
2023 | Gao et al. [27] | 110 | OS, PFS | Cervix ca. | RT | High pretreatment PLR (PLR > 187.88) was the independent risk factor for inferior OS; high PLR was associated with LN metastasis |
2023 | Li et al. [60] | 795 | OS | Cervix ca. | CRT | High pretreatment PLR (> 164.29) was independently associated with inferior OS |